Author(s):
Question:
Setting:
Bibliography:
Certainty assessment№ of patientsEffectCertaintyImportance
№ of studiesStudy designRisk of biasInconsistencyIndirectnessImprecisionOther considerationsBNP või Nt-proBNPainult kliiniline jälgimineRelative
(95% CI)		Absolute
(95% CI)
Üldsuremus (< 75 a) (follow-up: range 9 months to 36 months)
9a
randomised trials
serious
not serious
not serious
seriousb
none
248/1000 (24.8%)
HR 0.74
(0.55 to 1.00)
58 fewer per 1,000
(from 103 fewer to 0 fewer)
⨁⨁◯◯
Low
Üldsuremus (>75a) (follow-up: range 6 months to 36 months)
9c
randomised trials
serious
not serious
not serious
seriousb
none
353/1000 (35.3%)
HR 1.22
(0.81 to 1.85)
59 more per 1,000
(from 56 fewer to 200 more)
⨁⨁◯◯
Low
Hospitaliseerimine (<75a) (follow-up: range 6 months to 36 months)
4d
randomised trials
not serious
not serious
not serious
seriousb
none
696/1000 (69.6%)
HR 0.81
(0.66 to 0.99)
77 fewer per 1,000
(from 152 fewer to 4 fewer)
⨁⨁⨁◯
Moderate
Hospitaliseerimine (>75a) (follow-up: range 6 months to 36 months)
4e
randomised trials
not serious
not serious
not serious
seriousb
none
699/1000 (69.9%)
HR 1.03
(0.84 to 1.27)
11 more per 1,000
(from 64 fewer to 83 more)
⨁⨁⨁◯
Moderate
Hospitaliseerimine südamepuudulikkuse tõttu (follow-up: range 6 months to 36 months)
5f
randomised trials
serious
not serious
not serious
seriousb
none
245/1000 (24.5%)
HR 0.78
(0.61 to 0.99)
48 fewer per 1,000
(from 87 fewer to 2 fewer)
⨁⨁◯◯
Low
Neerupuudulikkuse süvenemine (follow-up: range 12 months to 24 months)
1g
randomised trials
serious
not serious
not serious
not serious
none
16/446 (3.6%)
9/448 (2.0%)
RR 1.79
(0.80 to 4.00)
16 more per 1,000
(from 4 fewer to 60 more)
⨁⨁⨁◯
Moderate
Hüperkaleemia (follow-up: range 18 months to 24 months)
1g
randomised trials
serious
not serious
not serious
not serious
none
11/446 (2.5%)
6/448 (1.3%)
RR 1.84
(0.69 to 4.94)
11 more per 1,000
(from 4 fewer to 53 more)
⨁⨁⨁◯
Moderate
Hüpotensioon (follow-up: range 10 months to 24 months)
3h
randomised trials
serious
not serious
not serious
not serious
none
18/555 (3.2%)
6/559 (1.1%)
OR 3.04
(1.34 to 7.07)
21 more per 1,000
(from 4 more to 61 more)
⨁⨁⨁◯
Moderate
Elukvaliteet (follow-up: mean 9 months; assessed with: KCCQ, MID=5)
1i
randomised trials
serious
not serious
not serious
not serious
none
126
124
-
MD 2.6 lower
(7.19 lower to 1.99 higher)
⨁⨁⨁◯
Moderate

CI: confidence interval; HR: hazard Ratio; MD: mean difference; OR: odds ratio; RR: risk ratio

Explanations

a. NICE 2018 metaanalüüsi kaasati kokku 9 juhuslikustatud kontrollitud uuringut ja 1234 uuritava andmeid: HTA Aggregate (7 studies), HTA IPD (Anguita), HTA IPD (NorthStar)
b. lai usaldusvahemik
c. NICE 2018 metaanalüüsi kaasati kokku 9 juhuslikustatud kontrollitud uuringut ja 1254 uuritava andmeid: HTA Aggregate (7 studies), HTA IPD (Anguita), HTA IPD (NorthStar)
d. NICE 2018 metaanalüüsi kaasati kokku 572 uuritavate andmed 4 RCT-st (HTA Aggregate (Time-CHF), HTA IPD (Anguita), HTA IPD (NorthStar), HTA IPD (UPSTEP))
e. NICE 2018 metaanalüüsi kaasati kokku 598 uuritavate andmed 4 RCT-st (HTA Aggregate (Time-CHF) HTA IPD (Anguita), HTA IPD (NorthStar), HTA IPD (UPSTEP)
f. NICE 2018 metaanalüüsi kaasatu 5 RCT (n= 1515) : Troughton Rev IPD (BATTLESCARRED), Troughton Rev IPD (Berger), Troughton Rev IPD (PRIMA), Troughton Rev IPD (PROTECT), Troughton Rev IPD (SIGNAL-HF)
g. Felker 2017 (GUIDE-IT), n=894
h. NICE metaanalüüsi kaasati 3 RCT (n=1114): Felker 2017 (GUIDE-IT), Januzzi 2011 (PROTECT), Troughton 2000 (Christchurch)
i. Persson 2010 (SIGNAL-HF), n=250